Journal of Heterocyclic Chemistry · 2005 · 24 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryStructure-activity RelationshipsAntineoplastic Drug ClassesHeterocyclic ChemistryBiological Evaluation PlanningBiological Evaluation Report
A number of thiosemicarbazones of 2-acetyl-imidazo[4,5-b]pyridine were prepared in order to investigate their in vitro antineoplastic activities. Three compounds: (i) 2-acetylimidazo[4,5-b]pyridin-4-sec-butyl-3-thiosemicarbazone [(A7), NSC674098], (ii) 2-acetylimidazo[4,5-b]pyridin-4-tert-butyl-3-thiosemi-carbazone [(A9), NSC674099], (iii) 2-acetylimidazo[4,5-b]pyridin-4-cyclohexyl-3-thiosemicarbozone [(A11), NSC674101] showed remarkable activity against some of the cell lines tested. The Biological Evaluation Committee of N.C.I. determined that further secondary testing should be carried out (these compounds were tested against prostate cancer).
15
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Cancer: Principles and Practice of Oncology.
Annals of Internal Medicine · 1988 · 1.9K citations
Medicine, Oncology, Oncology Nursing +10
Ribonucleotide Reductase and Cell Proliferation
Howard L. Elford, Michael Freese, Eugene R. Passamani et al. · Journal of Biological Chemistry · 1970 · 311 citations · Full text